In the published article, there was an error in Figures 2E, 2H, 4E as published. The micrometers on the scale were erroneously written as nanometers. The corrected Figures 2E, 2H, 4E, and their respective captions, appear below.
Figure 2
Preventive anti-biofilm potential of MSZ. (A) Effect of 0.5 mg/mL and 1 mg/mL MSZ on the overall biomass of P. gingivalis plaque biofilm formation and established plaque biofilms. (B) Histograms of the overall biomass of P. gingivalis plaque biofilm formation. (C) Histograms depicting total biomass distribution of pre-formed plaque biofilm spread. (D) Metabolic activity during plaque biofilm formation and (E) CLSM images of P. gingivalis plaque biofilm formation, including pre-formed plaque biofilms treated with varying MSZ concentrations. (F) Live bacteria ratio for P. gingivalis during plaque biofilm formation. (G) Live bacteria ratio for P. gingivalis in established plaque biofilm. (H) CLSM images depicting multispecies plaque biofilm formation and the effects of varying MSZ concentrations on pre-formed plaque biofilms. (I) Live bacteria ratio of multispecies plaque biofilm formation. (J) Live bacteria ratio of pre-formed multispecies plaque biofilm. Bars marked with (**), (***), and (****) represent significant differences at p < 0.01, p < 0.001, and p < 0.0001, respectively.
Figure 4
Effect of MSZ on the bone structure of the maxillary first molar in periodontitis rats. (A) Image of a periodontitis model. (B) Alveolar bone resorption of the maxillary first molar. The red line marks the CEJ-ABC distance. (C) Three-dimensional reconstruction and a sagittal micro-CT section of the maxillary first molar of rats in each group. (D) Micro-CT was used to analyze the bone structure parameters including BV/TV, Tb. Th, and Tb. Sp. The bar chart shows the CEJ-ABC distance. (E) H&E stained images of the periodontium were taken after 2 weeks post-treatment. First row of images (4×). Bars marked with (*) show a significant difference at p < 0.05.
The original version of this article has been updated.
Summary
Keywords
periodontitis, mesalazine, Porphyromonas gingivalis , plaque biofilm, inflammatory bowel disease
Citation
Frontiers Production Office (2025) Correction: Mesalazine: a novel therapeutic agent for periodontitis via regulation of periodontal microbiota and inhibiting Porphyromonas gingivalis. Front. Microbiol. 16:1638611. doi: 10.3389/fmicb.2025.1638611
Received
31 May 2025
Accepted
27 June 2025
Published
11 July 2025
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
16 - 2025
Updates
Copyright
© 2025 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.